세계의 다발성골수종 시장 규모는 2022년에 219억 8,000만 달러에 달하며, 2023년 253억 달러에서 2031년까지는 779억 3,000만 달러로 성장하며, 예측 기간(2024-2031년)의 CAGR은 15.1%로 성장할 전망입니다.
다발성골수종 시장은 주로 형질 세포를 침범하는 이 희귀 혈액암에 대한 인식이 높아지고 발병률이 증가함에 따라 큰 모멘텀을 보이고 있습니다. Globocan 2020 data 등의 보고서에 따르면 전 세계에서 1,929만 2,789명이 새로 암 진단을 받았으며, 암으로 인한 사망자 수는 약 1,000만 명에 달할 전망입니다. 약 1,000만 명입니다. 국제암연구소(IARC)는 이 수치가 2031년까지 2,750만 명의 신규 발병자와 1,630만 명의 사망자까지 증가할 것으로 예측하고 있으며, 남성이 여성보다 1.5배의 위험에 직면할 것으로 예상하고 있습니다. 주요 위험 요인으로는 흡연, 음주와 같은 생활습관, 남성의 높은 비만율 등이 꼽힙니다. 혈액암 발병률 증가와 의료 인프라, 연구 및 치료 옵션에 대한 수요 증가가 시장 성장에 기여하고 있습니다. 그러나 개발도상국의 낮은 치료율로 인해 세계 다발성골수종 시장의 성장이 다소 제한되고 있습니다. 현재 미국의 다발성골수종 시장은 헬스케어 부문이 이 문제를 해결하기 위해 노력하고 있으므로 향후 수년간 지속가능한 연평균 성장률(CAGR)을 유지할 것으로 예상됩니다.
Global Multiple Myeloma Market size was valued at USD 21.98 billion in 2022 and is poised to grow from USD 25.30 billion in 2023 to USD 77.93 billion by 2031, growing at a CAGR of 15.1% in the forecast period (2024-2031).
The multiple myeloma market is experiencing significant momentum driven by increasing awareness and rising incidence of this rare blood cancer, primarily affecting plasma cells. As new therapeutics continue to emerge, the competitive landscape is evolving, with a marked uptick in treatment expertise among leading market participants. Reports, such as the Globocan 2020 data, highlight a staggering 19,292,789 new cancer diagnoses worldwide, alongside nearly 10 million cancer-related fatalities. The International Agency for Research on Cancer (IARC) projects that these numbers will escalate to 27.5 million new cases and 16.3 million deaths by 2031, with men facing a 1.5-fold higher risk than women. Key risk factors include lifestyle choices like smoking, alcohol use, and higher obesity rates among men, while the disease predominantly affects older adults, particularly those aged 55 to 65. Contributing to market growth is the increasing incidence of hematological cancers and a growing demand for healthcare infrastructure, research, and treatment options. However, the proliferation of the global multiple myeloma market is somewhat curtailed by low treatment rates in developing nations. As it stands, the US multiple myeloma market is anticipated to maintain a sustainable compound annual growth rate (CAGR) in the forthcoming years, as the healthcare sector intensifies its focus on combating this challenging disease.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Myeloma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Multiple Myeloma Market Segmental Analysis
Global Multiple Myeloma Market is segmented on the drug class, therapy, distribution channel, and region. By drug class, market is segmented into Proteasome Inhibitors, Immunomodulatory Drugs, Monoclonal Antibodies, and Steroids. By therapy, market is segmented into immunotherapy, chemotherapy, radiation therapy, and stem cell transplant. By distribution channel, market is segmented into hospital, retail, and online pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Driver of the Global Multiple Myeloma Market
The global multiple myeloma market is significantly driven by the increasing adoption of monoclonal antibodies, which are heralded for their high safety profile and targeted action against myeloma cells. Advances in nanomedicine and microRNA therapies, alongside the ongoing development of effective and safe treatments, are further propelling market growth. The integration of monoclonal antibodies, like Darzalex and Empliciti, with existing therapies enhances treatment efficacy, attracting clinician preference. Additionally, the rising incidence of hematological cancers, particularly multiple myeloma linked to specific genetic mutations, coupled with an aging population and rising healthcare costs, are amplifying the demand for innovative treatment solutions within this market.
Restraints in the Global Multiple Myeloma Market
The global multiple myeloma market is significantly restrained by low treatment rates in emerging nations, primarily driven by the high cost of treatments, which limits patient access. Furthermore, the scarcity of skilled healthcare professionals and inadequate healthcare infrastructure in these regions compound the issue, hindering effective diagnosis and treatment. The COVID-19 pandemic has exacerbated this situation, resulting in a notable decline in clinical visits and heightened reluctance among patients to seek medical care. Additionally, a pervasive lack of public awareness regarding multiple myeloma remains a critical barrier, ultimately impeding the market's growth potential throughout the forecast period.
Market Trends of the Global Multiple Myeloma Market
The global multiple myeloma market is experiencing a significant upward trend driven by increased research and development activities. This surge is fostering the introduction of novel therapies, evidenced by a rise in drug approvals and market entries, particularly in monoclonal antibodies like Darzalex and Empliciti. These advancements not only offer innovative treatment options, extending relapse intervals for patients, but also complement traditional therapies such as Revlimid and Velcade. Additionally, the emergence of second-generation proteasome inhibitors like Ninlaro and Kyprolis further diversifies treatment strategies, enhancing patient outcomes and solidifying the market's growth trajectory in the coming years.